No profile data available.
Fate Therapeutics, Inc. (FATE) is a healthcare company in the additional cancer treatment drugs industry, based in San Diego, United States, with about 161 full-time employees.
It reported revenue of $6.65 million for fiscal year 2025, down 51.2% from fiscal year 2024, and net income of -$136.32 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $2.08 million, up 9.2% from a year before. Its market capitalization was $261.21 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Fate Therapeutics reported $6.65 million in revenue for fiscal year 2025, down 51.2% from $13.63 million in fiscal year 2024. In Q2 2026 revenue was $2.08 million.
$261.21 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Perspective Therapeutics, Inc. (CATX), CytoDyn Inc. (CYDY), Northwest Biotherapeutics, Inc. (NWBO), Zentalis Pharmaceuticals, Inc. (ZNTL).